Imidazole carboxamides: relationship of lipophilicity to activity against intracerebral murine glioma 26 and preliminary phase II clinical trial of 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) in primary and secondary brain tumors.

Suppr

超能文献

作者信息

Levin V A, Crafts D, Wilson C B, Kabra P, Hansch C, Boldrey E, Enot J, Neely M

出版信息

Cancer Chemother Rep. 1975 Mar-Apr;59(2 Pt 1):327-31.

PMID:1149010

Abstract

摘要

相似文献

Imidazole carboxamides: relationship of lipophilicity to activity against intracerebral murine glioma 26 and preliminary phase II clinical trial of 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) in primary and secondary brain tumors.

Cancer Chemother Rep. 1975 Mar-Apr;59(2 Pt 1):327-31.

5-[3,3-Bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) in the treatment of childhood malignancy.

Cancer Chemother Rep. 1975 Mar-Apr;59(2 Pt 1):371-6.

Comparative studies on the chemical stability and therapeutic effectiveness of water-insoluble 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196) and its water-soluble hydrochloride against L1210 mouse leukemia.

Cancer Chemother Rep. 1973 Nov-Dec;57(4):383-91.

Phase II study of 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196) in advanced gastrointestinal cancer.

Cancer Chemother Rep. 1972 Apr;56(2):267-9.

Value of cytosine arabinoside (NSC-63878) plus 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) therapy in advanced murine L1210 leukemia and enhancement of the combination with sequential doses of methotrexate (NSC-740) or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).阿糖胞苷（NSC - 63878）加5 -（3,3 - 二甲基 - 1 - 三氮烯）咪唑 - 4 - 甲酰胺（NSC - 45388）疗法在晚期小鼠L1210白血病中的价值以及与甲氨蝶呤（NSC - 740）或1,3 - 双（2 - 氯乙基）-1 - 亚硝基脲（卡莫司汀；NSC - 409962）序贯剂量联合使用时疗效的增强。

Cancer Chemother Rep. 1973 Sep-Oct;57(3):291-8.

Combination chemotherapy with CCNU (NSC-79037) and 5-(3, 3-bis(2-chloroethyl)-1-triazeno)-imidazole-4-carboxamide (NSC-82196).

Cancer Chemother Rep. 1975 Jul-Aug;59(4):769-71.

5-[3-(2-Chloroethyl)-1-triazenyl] imidazole-4-carboxamide and a possible mechanism of action of 5-[3, 3-bis(2-chloroethyl)-1-triazenyl] imidazole-4-carboxamide.

J Pharm Sci. 1975 Jan;64(1):177-80. doi: 10.1002/jps.2600640147.

Evaluation of 4-carbethoxy-5(3,3-dimethyl-1-triazeno)-2-phenylimidazole (NSC-166721) and 4-carbethoxy-5-(3,3-dimethyl-1-triazeno)-2-methylimidazole (NSC-166722) as potential antitumor agents.

Cancer Chemother Rep. 1973 Sep-Oct;57(3):263-8.

5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in the treatment of malignant tumors other than melanoma.

Cancer Chemother Rep. 1971 Jun;55(3):281-3.

Clinical experience with 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196) in the treatment of metastatic malignant melanoma.5-（3,3-双（2-氯乙基）-1-三氮烯基）咪唑-4-甲酰胺（NSC-82196）治疗转移性恶性黑色素瘤的临床经验

Cancer Chemother Rep. 1972 Oct;56(5):671-7.

引用本文的文献

Understanding brain penetrance of anticancer drugs.理解抗癌药物的脑穿透性。

Neuro Oncol. 2018 Apr 9;20(5):589-596. doi: 10.1093/neuonc/noy018.

CNS Anticancer Drug Discovery and Development Conference White Paper.中枢神经系统抗癌药物发现与开发会议白皮书。

Neuro Oncol. 2015 Nov;17 Suppl 6(Suppl 6):vi1-26. doi: 10.1093/neuonc/nov169.

Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas.以无进展生存期为终点的II期试验对间变性胶质瘤患者基于生存情况的III期研究的影响。

BMC Cancer. 2007 Jun 22;7:106. doi: 10.1186/1471-2407-7-106.

A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors.血脑屏障在人类脑肿瘤化疗中作用的批判性分析

J Neurooncol. 1994;20(2):121-39. doi: 10.1007/BF01052723.

Neuro-oncology index and review (adult primary brain tumors). Radiotherapy, chemotherapy, immunotherapy, photodynamic therapy.神经肿瘤学索引与综述（成人原发性脑肿瘤）。放射治疗、化学疗法、免疫疗法、光动力疗法。

J Neurooncol. 1991 Oct;11(2):85-147. doi: 10.1007/BF02390173.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验